JOINN Biologics US sells a deceptively practical service: finding out early whether a brilliant biologic can be made, measured and supplied. Its Richmond team now applies that logic from antibody screening to a 2026 biosimilar partnership.
Shawn Manchester is the CEO of Triplebar, an Emeryville-and-Oakland based biotech building generative AI 'genome language models' paired with ultra-high-throughput phenotypic screening to slash the cost of biologic therapeutics and food proteins. A chemical engineer by training (BS Brown, PhD MIT), he was the lead scientist in the first AI-versus-human strain engineering contest at Zymergen before joining Triplebar in 2021, where he rose from VP of Product to COO to CEO in March 2025.